Estrogen induces death of tamoxifen-resistant MCF-7 cells: Contrasting effect of the estrogen receptor downregulator fulvestrant

Journal of Steroid Biochemistry and Molecular Biology

Volumn 98, Issue 4-5, 2006, Pages 193-198

  Planas Silva, Maricarmen D ^a   Waltz, Paul K ^a   Kilker, Robin L ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Fulvestrant; Tamoxifen resistance

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ARTICLE; CELL DEATH; CELL STRAIN MCF 7; DOSE RESPONSE; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ESTROGEN BLOOD LEVEL; TUMOR GROWTH;

APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 33644753904     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.10.003     Document Type: Article

References (35)

1. R. Clarke, F. Leonessa, J.N. Welch, and T.C. Skaar Cellular and molecular pharmacology of antiestrogen action and resistance Pharmacol. Rev. 53 2001 25 71
2. R. Clarke, M.C. Liu, K.B. Bouker, Z. Gu, R.Y. Lee, Y. Zhu, T.C. Skaar, B. Gomez, K. O'Brien, Y. Wang, and L.A. Hilakivi-Clarke Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 2003 7316 7339
3. K. Yao, E.-S. Lee, D.J. Bentrem, G. England, J.I. Schafer, R.M. O'Regan, and V.C. Jordan Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice Clin. Cancer Res. 6 2000 2028 2036
4. H. Liu, E.-S. Lee, C. Gajdos, S.T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, and V.C. Jordan Apoptotic action of 17β-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo J. Natl. Cancer Inst. 95 2003 1586 1597
5. R.X.-D. Song, G. Mor, F. Naftolin, R.A. McPherson, J. Song, Z. Zhang, W. Yue, J. Wang, and R.J. Santen Effect of long-term estrogen deprivation on apoptotic responses of breast cancer to 17β-estradiol J. Natl. Cancer Inst. 93 2001 1714 1723
6. C.M.W. Chan, L.-A. Martin, S.R.D. Johnston, S. Ali, and M. Dowsett Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation J. Steroid Biochem. Mol. Biol. 81 2002 333 341
7. J.S. Lewis, C. Osipo, K. Meeke, and V.C. Jordan Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal J. Steroid Biochem. Mol. Biol. 94 2005 131 141
8. C. Osipo, C. Gajdos, H. Liu, B. Chen, and V.C. Jordan Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer J. Natl. Cancer Inst. 95 2003 1597 1608
9. R.L. Kilker, M.W. Hartl, T.M. Rutherford, and M.D. Planas-Silva Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells J. Steroid Biochem. Mol. Biol. 92 2004 63 71
10. A. Howell, D.J. DeFriend, J.F.R. Robertson, R.W. Blamey, L. Anderson, E. Anderson, F.A. Sutcliffe, and P. Walton Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer Br. J. Cancer 74 1996 300 308
11. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
12. K. McKeage, M.P. Curran, and G.L. Plosker Fulvestrant a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy Drugs 64 2004 633 648
13. S. Legault-Poisson, J. Jolivet, R. Poisson, M. Beretta-Piccoli, and P.R. Band Tamoxifen-induced tumor stimulation and withdrawal response Cancer Treat. Rep. 63 1979 1839 1841
14. W.I. Stein, G.N. Hortobagyi, and G.R. Blumenschein Response of metastatic breast cancer to tamoxifen withdrawal: report of a case J. Surg. Oncol. 22 1983 45 46
15. C.P. Belani, P. Pearl, N.O. Whitley, and J. Aisner Tamoxifen withdrawal response. Report of a case Arch. Intern. Med. 149 1989 449 450
16. A. Howell, D.J. Dodwell, H. Anderson, and J. Redford Response after withdrawal of tamoxifen and progestogens in advanced breast cancer Ann. Oncol. 3 1992 611 617
17. S.G.I. Taylor, R.S. Gelman, G. Falkson, and F.J. Cummings Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women Ann. Inter. Med. 104 1986 455 461
18. P.E. Lonning, P.D. Taylor, G. Anker, J. Iddon, L. Wie, L.M. Jorgensen, O. Mella, and A. Howell High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy Breast Cancer Res. Treat. 67 2001 111 116
19. P.P. Peethambaram, J.N. Ingle, V.J. Suman, L.C. Hartmann, and C.L. Loprinzi Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis Breast Cancer Res. Treat. 54 1999 117 122
20. J.N. Ingle Estrogen as therapy for breast cancer Breast Cancer Res. 4 2002 133 136
21. L.H. Baker, and V.K. Vaitkevicius Reevaluation of rebound regression in disseminated carcinoma of the breast Cancer 29 1972 1268 1271
22. R.J. Kaufman, and G.C. Escher Rebound regression in advanced mammary carcinoma Surg. Gynecol. Obstet. 113 1961 635 640
23. R.W. Nesto, B. Cady, R.A. Oberfield, A.G. Pazianos, and F.A. Salzman Rebound response after estrogen therapy for metastatic breast cancer Cancer 38 1976 1834 1837
24. A. Howell Future use of selective estrogen receptor modulators and aromatase inhibitors Clin. Cancer Res. 7 2001 4402s 4410s
25. J.S. Lewis, D. Cheng, and V.C. Jordan Targeting oestrogen to kill the cancer but not the patient Br. J. Cancer 90 2004 944 949
26. J.E. Mortimer, F. Dehdashti, B.A. Siegel, K. Trinkaus, J.A. Katzenellenbogen, and M.J. Welch Metabolic flare: indicator of hormone responsiveness in advanced breast cancer J. Clin. Oncol. 19 2001 2797 2803
27. C.M.L. West, T. Jones, and P. Price The potential of positron-emission tomography to study anticancer-drug resistance Nat. Rev. Cancer 4 2004 457 469
28. R.J. Bennink, G. van Tienhoven, L. Rijks, A.L. Noorduyn, A.G. Janssen, and G.W. Sloof In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer J. Nucl. Med. 45 2004 1 7
29. A.C. Carter, N. Sedransk, R.M. Kelley, F.J. Ansfield, R.G. Ravdin, R.W. Talley, and N.R. Potter Diethylstilbestrol: recommended dosages for different categories of breast cancer patients JAMA 237 1977 2079 2085
30. A. Howell, J.F.R. Robertson, P. Abram, M.R. Lichinitser, R. Elledge, E. Bajetta, T. Watanabe, C. Morris, A. Webster, I. Dimery, and C.K. Osborne Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J. Clin. Oncol. 22 2004 1605 1613
31. A. Howell, D. DeFriend, J.F.R. Robertson, R.W. Blamey, and P. Walton Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer Lancet 345 1995 29 30
32. A. Howell, J.F.R. Robertson, J.Q. Albano, A. Aschermannova, L. Mauriac, U.R. Kleeberg, I. Vergote, B. Erikstein, A. Webster, and C. Morris Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J. Clin. Oncol. 20 2002 3396 3403
33. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
34. G.A. Kuchel, C. Tannenbaum, S.L. Greenspan, and N.M. Resnick Can variability in the hormonal status of elderly women assist in the decision to administer estrogens? J. Women's Health Gender-Based Med. 10 2001 109 116
35. J.R. Pasqualini The selective estrogen enzyme modulators in breast cancer: a review Biochim. Biophys. Acta 1654 2004 123 143